Metformin in Women With Type 2 Diabetes in Pregnancy Trial (MiTy)
This study is currently recruiting participants.
(see Contacts and Locations)
Verified May 2016 by Mount Sinai Hospital, Canada
Sponsor:
Mount Sinai Hospital, Canada
Collaborators:
University Health Network, Toronto
Sunnybrook Research Institute
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
Mount Sinai Hospital, Canada
ClinicalTrials.gov Identifier:
NCT01353391
First received: May 2, 2011
Last updated: May 4, 2016
Last verified: May 2016
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Insulin is the standard treatment for the management of type 2 diabetes in pregnancy, however despite treatment with insulin, these women continue to face increased rates of adverse maternal and fetal outcomes. The investigators hypothesize that metformin use, in addition to treatment with insulin, will help with blood sugar control, lower the dose of insulin needed, lower weight gain, and improve baby outcomes.
| Condition | Intervention | Phase |
|---|---|---|
|
Type 2 Diabetes |
Drug: Metformin Drug: Placebo Comparator |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Metformin in Women With Type 2 Diabetes in Pregnancy Trial |
Resource links provided by NLM:
Further study details as provided by Mount Sinai Hospital, Canada:
Primary Outcome Measures:
- A composite of: pregnancy loss, preterm birth, birth injury, moderate/severe respiratory distress, neonatal hypoglycemia, and NICU admission > 24 hours. [ Time Frame: conception to 28 days after birth ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Large for gestational age (LGA) infants [ Time Frame: Up to 24 hours after birth ] [ Designated as safety issue: Yes ]Defined as greater than the 90th percentile for weight, based on the National canadian fetal growth standards for singleton boys and girls.
- Pregnancy loss [ Time Frame: Up to 40 weeks gestation ] [ Designated as safety issue: Yes ]Spontaneous abortion defined as death of a fetus at <20 weeks gestation; Stillbirth defined as death of a fetus with a birth weight ≥ 500g or at ≥ 20 wks gestational age regardless of birth weight; Neonatal death defined as death of a live born infant within the first 28 days of life or prior to hospital discharge, whichever is later.
- Preterm birth [ Time Frame: Up to 37 weeks gestation ] [ Designated as safety issue: Yes ]Birth < 37 weeks gestation
- Respiratory distress [ Time Frame: within 72 hours after birth ] [ Designated as safety issue: Yes ]Given surfactant via an endotracheal tube and/or requiring assisted positive pressure ventilation within 72 hours after birth.
- Neonatal hypoglycemia [ Time Frame: NICU admission >24 hours ] [ Designated as safety issue: Yes ]A plasma glucose <2.6 mmol/L on one or more occasions, starting at 30-60 minutes after birth, and necessitating intravenous dextrose within the first 48 hours of life.
- NICU admission >24 hours [ Time Frame: NICU admission >24 hours ] [ Designated as safety issue: Yes ]Admission to a neonatal intensive or special care unit for > 24 hours during the initial hospitalization after birth
- Cord blood gases pH <7.0 [ Time Frame: Within 4 hours of birth ] [ Designated as safety issue: Yes ]
- Hyperinsulinemia as measured by elevated cord blood C-peptide [ Time Frame: Within 4 hours of birth ] [ Designated as safety issue: No ]A cord serum C-peptide value > 1.7 ug/L (which is >90th percentile of values for the total cohort of participants in the HAPO trial) will be defined as hyperinsulinemia.
- Maternal glycemic control as measured by HbA1c and capillary glucose measurements. [ Time Frame: Up to 40 weeks gestation ] [ Designated as safety issue: Yes ]Gestational age at testing will be recorded. All downloaded glucose results will be transmitted on a regular basis to a central site for future analysis. Monthly correlations will be done with the laboratory during routine monthly blood draws.
- Maternal hypoglycemia [ Time Frame: Up to 40 weeks gestation ] [ Designated as safety issue: Yes ]Maternal hypoglycemia defined as mild (<3.6, symptomatic and asymptomatic or requiring treatment), or severe (loss of consciousness or confusion requiring assistance) will be documented at each visit.
- Maternal weight gain [ Time Frame: Up to 40 weeks gestation ] [ Designated as safety issue: Yes ]The first and last weight will be obtained at the first and last visit in pregnancy, whether they be done by the endocrinologist, family physician or obstetrician.
- Maternal insulin doses [ Time Frame: Up to 40 weeks gestation ] [ Designated as safety issue: Yes ]Maternal insulin doses (overall amount and number of patients that are taking 'high' insulin doses defined as 2 Units/kg or more per day)
- Pre-eclampsia, and/or gestational hypertension [ Time Frame: Up to 40 weeks gestation ] [ Designated as safety issue: Yes ]
Gestational hypertension: New onset of hypertension in pregnancy ≥ 20 weeks gestation in a woman with previously normal blood pressure, defined as diastolic blood pressure of ≥ 90 mmHg, taken on 2 occasions or placed on antihypertensive medication and without proteinuria.
Pre-eclampsia: please refer to protocol for definition
- Sepsis [ Time Frame: Up to 28 days after birth ] [ Designated as safety issue: Yes ]A positive blood and/or cerebral spinal fluid culture during the neonatal hospital stay.
- Hyperbilirubinemia [ Time Frame: First 7 days of life ] [ Designated as safety issue: Yes ]Significant jaundice was present based on bilirubin levels requiring treatment with phototherapy> 6 continuous hours, or an exchange transfusion, or receiving intravenous gamma globulin, or requiring readmission into hospital during the first 7 days of life.
- Number of hospitalizations [ Time Frame: Up to 40 weeks gestation ] [ Designated as safety issue: No ]Number of hospitalizations prior to admission for delivery and the duration of hospital stays for the mother prior to admission for delivery and associated with delivery.
- Rate of caesarean-section [ Time Frame: Up to 40 weeks gestation ] [ Designated as safety issue: Yes ]
- Duration of hospital stay for infant. [ Time Frame: Up to 28 days after birth ] [ Designated as safety issue: No ]Duration of hospital stay for infant associated with his/her birth until the first discharge home
- Fetal fat mass [ Time Frame: Up to 7 days after birth ] [ Designated as safety issue: Yes ]Fetal fat mass compared with women treated with insulin plus placebo
- Birth Injury [ Time Frame: Up to 7 days after birth ] [ Designated as safety issue: Yes ]Defined as any of the following: spinal cord injury, basal skull fracture or depressed skull fracture, clavicular fracture, long bone fracture, subdural or intracerebral hemorrhage or any kind
- Shoulder dystocia [ Time Frame: At delivery ] [ Designated as safety issue: Yes ]Documentation of any shoulder dystocia in the delivery records, plus 3 or more of the following: McRoberts maneuver, suprapubic maneuver, episiotomy, delivery of the posterior arm, Woods maneuver, Rubins maneuver, All fours Gaskins maneuver, intentional fracture of the clavicle, and/or Zavenelli maneuver.
| Estimated Enrollment: | 500 |
| Study Start Date: | May 2011 |
| Estimated Study Completion Date: | December 2016 |
| Estimated Primary Completion Date: | December 2016 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Metformin |
Drug: Metformin
500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
|
| Placebo Comparator: Sugar pill |
Drug: Placebo Comparator
Sugar Pill
|
Detailed Description:
Type 2 diabetes in pregnancy is increasing in prevalence and these women continue to face increased rates of adverse maternal and fetal outcomes. The investigators hypothesize that metformin use, as an adjunct to insulin, will decrease these adverse outcomes by reducing maternal hyperglycemia, high maternal insulin doses, excessive maternal weight gain and gestational hypertension/pre-eclampsia, all of which should reduce perinatal and neonatal mortality and morbidity. In addition, since metformin crosses the placenta, metformin treatment of the fetus may have a direct beneficial effect on neonatal outcomes. This study is an randomized controlled trial (RCT) that adds metformin to insulin, and is a double-blind, placebo-controlled RCT. The investigators believe that neither metformin alone nor insulin alone will effectively treat this population, and therefore our design, which includes the addition of metformin to insulin, will be the most relevant to our patients.
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Women who are between of 18-45 years of age.
-
(i). Women diagnosed with type 2 diabetes prior to pregnancy, OR (ii). Women with undiagnosed type 2 diabetes diagnosed prior to 20 weeks gestation, defined as women presenting with gestational diabetes before 20 weeks gestation with various combinations, as per Canadian Diabetes Association, including:
- 2 fasting glucose ≥ 7.0 mmol/L, or
- 2 HbA1c of ≥0.065 (6.5%) performed in a laboratory using a method that is standardized to the Diabetes Control and Complications Trial (DCCT) assay, or
- 1 fasting glucose ≥7.0 mmol/L and 1 HbA1c ≥ 0.065 (6.5%) performed in a laboratory using a method that is standardized to the DCCT assay, or
- 1 fasting glucose ≥ 7.0 mmol/L and 1 two hour (2 hr) ≥ 11.1 on a 75 g Oral Glucose Tolerance Test (OGTT), or
- 1 HbA1C ≥0.065 (6.5%) performed in a laboratory using a method that is standardized to the DCCT assay and 1 two hour (2 hr) ≥ 11.1 on a 75 g OGTT.
- Pregnancy gestation between 6+0-22+6 weeks.
- Live singleton fetus.
Exclusion Criteria:
- Women who are not on insulin. Women who are on oral hypoglycemic agents will be taken off at the start of the trial and started on insulin prior to randomization.
- Diabetes diagnosed after 20 weeks gestation.
- Type 1 diabetes.
- Known intolerance to metformin.
- Contraindications to metformin use which include:
(i). Renal insufficiency (defined as serum creatinine of greater than 130 µmol/L or creatinine clearance <60 ml/min) , (ii). Moderate to severe liver dysfunction (defined as liver enzymes (aspartate aminotransferase (AST) and alanine aminotransferase (ALT)) greater than 3 times the upper limit of normal), (iii). Shock or sepsis, and (iv.) Previous hypersensitivity to metformin.
f. Women with significant gastrointestinal problems such as severe vomiting requiring IV fluids or hospitalization, or active Crohn's or colitis.
g. Previous participation in the trial. h. Women who have a fetus with a known potentially lethal anomaly will be excluded. Information regarding congenital anomalies diagnosed after randomization will be recorded.
i. Known higher order pregnancies (twins, triplets, etc). These women will be excluded as they have a higher rate of adverse outcomes and we want to avoid any inequalities if they are unequally distributed between the groups.
j. Presence of acute or chronic metabolic acidosis, including diabetic ketoacidosis.
k. History of diabetic ketoacidosis or history of lactic acidosis. l. Presence of excessive alcohol intake, acute or chronic. m. Presence of congestive heart failure or history of congestive heart failure.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01353391
Please refer to this study by its ClinicalTrials.gov identifier: NCT01353391
Contacts
| Contact: Siobhan Tobin, Hon.B.Sc. | 416-480-5631 | mity@sunnybrook.ca | |
| Contact: Johanna Sanchez, MIPH | 416-480-5628 | johanna.sanchez@sunnybrook.ca |
Locations
| Canada, Ontario | |
| The Centre for Mother, Infant, and Child Research, Sunnybrook Research Institute | Recruiting |
| Toronto, Ontario, Canada, M4N 3M5 | |
| Contact: Siobhan Tobin, Hon.B.Sc. 416-480-5631 mity@sunnybrook.ca | |
| Contact: Trinh Hoac, MIPH 416-480-6100 ext 87535 trinh.hoac@sunnybrook.ca | |
| Sub-Investigator: Shital Gandhi, MD | |
Sponsors and Collaborators
Mount Sinai Hospital, Canada
University Health Network, Toronto
Sunnybrook Research Institute
Canadian Institutes of Health Research (CIHR)
Investigators
| Principal Investigator: | Denice Feig, MD | Mount Sinai Hospital, New York |
More Information
Additional Information:
| Responsible Party: | Mount Sinai Hospital, Canada |
| ClinicalTrials.gov Identifier: | NCT01353391 History of Changes |
| Other Study ID Numbers: | MOP-106678 |
| Study First Received: | May 2, 2011 |
| Last Updated: | May 4, 2016 |
| Health Authority: | Canada: Canadian Institutes of Health Research (CIHR) Canada: Health Canada |
Keywords provided by Mount Sinai Hospital, Canada:
|
Diabetes MiTy Metformin in Women Type 2 Diabetes Pregnancy |
Additional relevant MeSH terms:
|
Diabetes Mellitus, Type 2 Diabetes Mellitus Pregnancy in Diabetics Diabetes, Gestational Glucose Metabolism Disorders Metabolic Diseases |
Endocrine System Diseases Pregnancy Complications Metformin Hypoglycemic Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on September 23, 2016